PharmaTimes | in-depth news, features and insights for the pharmaceutical and healthcare sectors

.tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end}[data-toolset-views-view-pagination-block="b5ee7a93952c82ad8154125da3a7733a"] ul { text-align: center;justify-content: center; } .tb-container .tb-container-inner{width:100%;margin:0 auto} .wp-block-toolset-blocks-container.tb-container[data-toolset-blocks-container="2c43613e993e2394568fe34903b86a0f"] { background:linear-gradient(rgba( 0, 0, 0, 0.13 ),rgba( 0, 0, 0, 0.13 )),   url('https://pharmatimes.com/wp-content/uploads/2023/12/AI.jpg') center center no-repeat;background-size:auto, cover;padding: 25px;min-height: 500px;display:ms-flexbox !important;display:flex !important;-ms-flex-direction:column;flex-direction:column;-ms-flex-pack:center;justify-content:center; } .tb-container .tb-container-inner{width:100%;margin:0 auto} .wp-block-toolset-blocks-container.tb-container[data-toolset-blocks-container="25729c831f4b8caf3a7382396af662f4"] { background: rgba( 110, 110, 110, 0.43 );padding: 15px 25px 15px 25px; } .tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em} .tb-button[data-toolset-blocks-button="37dad1b8a003c5dbbfa7f1938d6759a2"] .tb-button__link { background-color: rgba( 255, 255, 255, 0 );color: rgba( 255, 255, 255, 1 );border: 2px solid rgba( 255, 255, 255, 1 );font-weight: bold;color: rgba( 255, 255, 255, 1 ); } .tb-container .tb-container-inner{width:100%;margin:0 auto}h2.tb-heading[data-toolset-blocks-heading="3b7ed8e4afda9e2b6b6174785a4c06c4"]  { font-size: 42px;font-family: Merriweather;font-weight: bold;color: rgba( 255, 255, 255, 1 );text-align: left; }  @media only screen and (max-width: 781px) { .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end}.tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em}.tb-container .tb-container-inner{width:100%;margin:0 auto}  } @media only screen and (max-width: 599px) { .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end}.tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em}.tb-container .tb-container-inner{width:100%;margin:0 auto}  } 

In therapies

Ten exciting new pharmaceutical drugs emerging in 2026

News

FDA approves new high dose Spinraza regimen for SMA

Apr 1, 2026

Updated dosing offers meaningful clinical benefit

Viridian reports positive results from elegrobart phase 3 trial

Apr 1, 2026

Company says treatment shows strong efficacy and convenient dosing profile

Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call

Mar 31, 2026

Specialist group to review preclinical and clinical proposals ahead of funding decision

Kygevvi approved in Europe as first treatment for TK2d

Mar 31, 2026

European Commission authorises therapy for children and adults with early‑onset disease

Tozorakimab shows significant benefit in two major COPD trials

Mar 30, 2026

Phase 3 studies report meaningful reductions in exacerbations across broad patient groups

Daratumumab becomes first oncology injectable approved for patient administration

Mar 30, 2026

CHMP decision allows self‑administration from phase 5 for people with multiple myeloma

Web Exclusives

True colours

Jan 15, 2026

The gold standard in spectroscopy

Trust issues

Oct 24, 2025

Specialty pharmacies – a guide to regulatory bodies and standards

Leader of the packs

Oct 1, 2025

3 Packaging Companies that offer custom pharmaceutical packaging solutions

Fertile ground

Aug 24, 2025

Top-rated pharmacies in northern Virginia for personalised fertility care

Magazine

April 2026

Apr 1, 2026

This month’s edition reimagines the NHS dichotomy as a dystopian game of Tetris – we investigate which parties might finally shake things up. We explore the GLP-1 explosion and how its boom will mold the medicines of the future. Plus, deep dives into AI in pharma, reproductive health in 2026, life sciences’ greatest hits, and the global impact of Trump’s healthcare decisions. Finally, comms guru Jess ‘Pharmery’ Farmery sparkles in her highly anticipated debut.